| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.81 [0.67, 0.99] | | < 1 | | 58% | 3 studies (3/-) | 98.1 % | some concern | not evaluable | moderate | crucial | - |
| deaths (OS) (extension) | 0.66 [0.55, 0.80] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
| PFS (extension) | 0.68 [0.57, 0.82] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
| progression or deaths (PFS) | 0.79 [0.64, 0.97] | | < 1 | | 42% | 3 studies (3/-) | 98.8 % | some concern | not evaluable | moderate | important | - |
| objective responses (ORR) | 1.48 [0.84, 2.64] | | > 1 | | 75% | 3 studies (3/-) | 91.1 % | some concern | not evaluable | moderate | non important | - |
safety endpoints 00 |
| AE (any grade) | 0.53 [0.30, 0.91] | | < 1 | | 0% | 2 studies (2/-) | 98.9 % | some concern | not evaluable | moderate | non important | - |
| AE (grade 3-4) | 0.88 [0.61, 1.27] | | < 1 | | 44% | 2 studies (2/-) | 74.6 % | some concern | not evaluable | moderate | non important | - |
| AE leading to death (grade 5) | 1.93 [1.14, 3.29] | | < 1 | | 0% | 2 studies (2/-) | 0.8 % | some concern | not evaluable | moderate | non important | - |
| AE leading to treatment discontinuation (any grade) | 1.33 [0.95, 1.84] | | < 1 | | 0% | 2 studies (2/-) | 4.7 % | some concern | not evaluable | moderate | non important | - |
| AE leading to treatment discontinuation (grade 3-4) | 2.14 [1.32, 3.47] | | < 1 | | 0% | 1 study (1/-) | 0.1 % | NA | not evaluable | | non important | - |
| SAE (any grade) | 1.86 [1.31, 2.62] | | < 1 | | 0% | 2 studies (2/-) | 0.0 % | some concern | not evaluable | moderate | non important | - |
| STRAE (any grade) | 1.73 [1.33, 2.25] | | < 1 | | 0% | 2 studies (2/-) | 0.0 % | some concern | not evaluable | moderate | non important | - |
| STRAE (grade 3-4) | 1.70 [1.26, 2.30] | | < 1 | | 10% | 2 studies (2/-) | 0.0 % | some concern | not evaluable | moderate | non important | - |
| TRAE (any grade) | 0.57 [0.21, 1.55] | | < 1 | | 93% | 3 studies (3/-) | 86.4 % | some concern | not evaluable | moderate | non important | - |
| TRAE (grade 3-4) | 0.74 [0.36, 1.53] | | < 1 | | 91% | 3 studies (3/-) | 79.1 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to death (grade 5) | 1.34 [0.58, 3.12] | | < 1 | | 0% | 3 studies (3/-) | 24.8 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to discontinuation (any grade) | 2.06 [1.22, 3.47] | | < 1 | | 61% | 3 studies (3/-) | 0.3 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to discontinuation (grade 3-4) | 3.26 [2.13, 4.99] | | < 1 | | 0% | 2 studies (2/-) | 0.0 % | some concern | not evaluable | moderate | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Acute kidney injury TRAE (grade 3-4) | 1.27 [0.04, 38.28] | | < 1 | | 0% | 1 study (1/-) | 44.5 % | NA | not evaluable | | non important | - |
| Adrenal insufficiency TRAE (grade 3-4) | 4.26 [0.71, 25.42] | | < 1 | | 0% | 3 studies (3/-) | 5.7 % | some concern | not evaluable | moderate | non important | - |
| Alopecia TRAE (grade 3-4) | 0.95 [0.02, 47.95] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Anaemia TRAE (grade 3-4) | 0.14 [0.02, 0.87] | | < 1 | | 65% | 3 studies (3/-) | 98.2 % | some concern | not evaluable | moderate | non important | - |
| Asthenia TRAE (grade 3-4) | 0.31 [0.10, 0.99] | | < 1 | | 1% | 3 studies (3/-) | 97.6 % | some concern | not evaluable | moderate | non important | - |
| Colitis TRAE (grade 3-4) | 8.18 [1.51, 44.34] | | < 1 | | 0% | 3 studies (3/-) | 0.8 % | some concern | not evaluable | moderate | non important | - |
| Constipation TRAE (grade 3-4) | 0.65 [0.05, 8.42] | | < 1 | | 0% | 2 studies (2/-) | 63.0 % | some concern | not evaluable | moderate | non important | - |
| Decreased appetite TRAE (grade 3-4) | 0.88 [0.37, 2.14] | | < 1 | | 0% | 3 studies (3/-) | 60.8 % | some concern | not evaluable | moderate | non important | - |
| Diabetes TRAE (grade 3-4) | 1.90 [0.06, 56.82] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
| Diarrhoea TRAE (grade 3-4) | 5.02 [1.92, 13.10] | | < 1 | | 0% | 3 studies (3/-) | 0.0 % | some concern | not evaluable | moderate | non important | - |
| Dyspnoea TRAE (grade 3-4) | 2.56 [0.11, 57.33] | | < 1 | | 0% | 1 study (1/-) | 27.9 % | NA | not evaluable | | non important | - |
| Fatigue TRAE (grade 3-4) | 1.22 [0.42, 3.57] | | < 1 | | 47% | 3 studies (3/-) | 35.5 % | some concern | not evaluable | moderate | non important | - |
| Febrile neutropenia TRAE (grade 3-4) | 1.38 [0.60, 3.15] | | < 1 | | 0% | 1 study (1/-) | 22.3 % | NA | not evaluable | | non important | - |
| Hepatitis TRAE (grade 3-4) | 4.15 [0.64, 26.90] | | < 1 | | 8% | 2 studies (2/-) | 6.8 % | some concern | not evaluable | moderate | non important | - |
| Hypersensitivity TRAE (grade 3-4) | 1.27 [0.04, 38.28] | | < 1 | | 0% | 1 study (1/-) | 44.5 % | NA | not evaluable | | non important | - |
| Hypertension TRAE (grade 3-4) | 1.27 [0.11, 14.23] | | < 1 | | 0% | 1 study (1/-) | 42.2 % | NA | not evaluable | | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 1.19 [0.09, 15.52] | | < 1 | | 0% | 2 studies (2/-) | 44.8 % | some concern | not evaluable | moderate | non important | - |
| Hypophysitis TRAE (grade 3-4) | 1.56 [0.14, 17.23] | | < 1 | | 0% | 2 studies (2/-) | 36.0 % | some concern | not evaluable | moderate | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 2.33 [0.33, 16.43] | | < 1 | | 0% | 3 studies (3/-) | 19.8 % | some concern | not evaluable | moderate | non important | - |
| Increase AST TRAE (grade 3-4) | 0.63 [0.01, 32.23] | | < 1 | | 0% | 1 study (1/-) | 58.8 % | NA | not evaluable | | non important | - |
| Increased ALT TRAE (grade 3-4) | 1.73 [0.42, 7.13] | | < 1 | | 0% | 2 studies (2/-) | 22.5 % | some concern | not evaluable | moderate | non important | - |
| Increased lipase level TRAE (grade 3-4) | 4.56 [0.64, 32.21] | | < 1 | | 28% | 2 studies (2/-) | 6.5 % | some concern | not evaluable | moderate | non important | - |
| Infusion-related reactions TRAE (grade 3-4) | 0.63 [0.01, 32.23] | | < 1 | | 0% | 1 study (1/-) | 58.8 % | NA | not evaluable | | non important | - |
| Leucopenia TRAE (grade 3-4) | 0.10 [0.01, 2.08] | | < 1 | | 0% | 1 study (1/-) | 92.8 % | NA | not evaluable | | non important | - |
| Maculopapular rash TRAE (grade 3-4) | 4.93 [0.57, 42.41] | | < 1 | | 0% | 1 study (1/-) | 7.4 % | NA | not evaluable | | non important | - |
| Myositis TRAE (grade 3-4) | 0.63 [0.01, 32.23] | | < 1 | | 0% | 1 study (1/-) | 58.8 % | NA | not evaluable | | non important | - |
| Nausea TRAE (grade 3-4) | 0.63 [0.12, 3.21] | | < 1 | | 38% | 3 studies (3/-) | 71.0 % | some concern | not evaluable | moderate | non important | - |
| Nephritis TRAE (grade 3-4) | 0.95 [0.02, 47.95] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Neutropenia TRAE (grade 3-4) | 0.08 [0.00, 1.55] | | < 1 | | 84% | 3 studies (3/-) | 95.1 % | some concern | not evaluable | moderate | non important | - |
| Pancreatitis TRAE (grade 3-4) | 2.56 [0.11, 57.33] | | < 1 | | 0% | 1 study (1/-) | 27.9 % | NA | not evaluable | | non important | - |
| Peripheral oedema TRAE (grade 3-4) | 1.27 [0.04, 38.28] | | < 1 | | 0% | 1 study (1/-) | 44.5 % | NA | not evaluable | | non important | - |
| Pneumonia TRAE (grade 3-4) | 0.63 [0.01, 32.23] | | < 1 | | 0% | 1 study (1/-) | 58.8 % | NA | not evaluable | | non important | - |
| Pneumonitis TRAE (grade 3-4) | 7.30 [1.34, 39.79] | | < 1 | | 0% | 2 studies (2/-) | 1.1 % | some concern | not evaluable | moderate | non important | - |
| Pruritic rash TRAE (grade 3-4) | 1.27 [0.04, 38.28] | | < 1 | | 0% | 1 study (1/-) | 44.5 % | NA | not evaluable | | non important | - |
| Pruritus TRAE (grade 3-4) | 1.98 [0.26, 15.16] | | < 1 | | 0% | 3 studies (3/-) | 25.7 % | some concern | not evaluable | moderate | non important | - |
| Pyrexia TRAE (grade 3-4) | 0.32 [0.01, 9.50] | | < 1 | | 0% | 1 study (1/-) | 74.3 % | NA | not evaluable | | non important | - |
| Rash TRAE (grade 3-4) | 1.36 [0.17, 11.00] | | < 1 | | 45% | 3 studies (3/-) | 38.6 % | some concern | not evaluable | moderate | non important | - |
| Stomatitis TRAE (grade 3-4) | 1.27 [0.04, 38.28] | | < 1 | | 0% | 1 study (1/-) | 44.5 % | NA | not evaluable | | non important | - |
| Thrombocytopenia TRAE (grade 3-4) | 0.22 [0.02, 2.51] | | < 1 | | 72% | 3 studies (3/-) | 88.8 % | some concern | not evaluable | moderate | non important | - |
| Thyroiditis TRAE (grade 3-4) | 0.63 [0.01, 32.23] | | < 1 | | 0% | 1 study (1/-) | 58.8 % | NA | not evaluable | | non important | - |
| Vomiting TRAE (grade 3-4) | 0.44 [0.07, 2.61] | | < 1 | | 43% | 3 studies (3/-) | 81.7 % | some concern | not evaluable | moderate | non important | - |
| Weight decreased TRAE (grade 3-4) | 1.27 [0.04, 38.28] | | < 1 | | 0% | 1 study (1/-) | 44.5 % | NA | not evaluable | | non important | - |
AE (grade 3-4) endpoints 00 |
| Alopecia AE (grade 3-4) | 0.95 [0.02, 47.95] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Anaemia AE (grade 3-4) | 0.12 [0.05, 0.28] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| Asthenia AE (grade 3-4) | 0.86 [0.36, 2.05] | | < 1 | | 0% | 1 study (1/-) | 63.4 % | NA | not evaluable | | non important | - |
| Back pain AE (grade 3-4) | 0.63 [0.10, 3.80] | | < 1 | | 0% | 1 study (1/-) | 69.2 % | NA | not evaluable | | non important | - |
| Constipation AE (grade 3-4) | 1.90 [0.17, 21.07] | | < 1 | | 0% | 1 study (1/-) | 30.1 % | NA | not evaluable | | non important | - |
| Cough AE (grade 3-4) | 0.95 [0.02, 47.95] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Decreased appetite AE (grade 3-4) | 1.43 [0.40, 5.11] | | < 1 | | 0% | 1 study (1/-) | 29.1 % | NA | not evaluable | | non important | - |
| Diarrhoea AE (grade 3-4) | 2.12 [0.73, 6.17] | | < 1 | | 0% | 1 study (1/-) | 8.4 % | NA | not evaluable | | non important | - |
| Dyspnoea AE (grade 3-4) | 1.11 [0.37, 3.33] | | < 1 | | 0% | 1 study (1/-) | 42.7 % | NA | not evaluable | | non important | - |
| Fatigue AE (grade 3-4) | 1.31 [0.52, 3.31] | | < 1 | | 0% | 1 study (1/-) | 28.1 % | NA | not evaluable | | non important | - |
| Nausea AE (grade 3-4) | 0.63 [0.18, 2.25] | | < 1 | | 0% | 1 study (1/-) | 76.2 % | NA | not evaluable | | non important | - |
| Neutropenia AE (grade 3-4) | 0.01 [0.00, 0.19] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | non important | - |
| Pruritus AE (grade 3-4) | 0.95 [0.02, 47.95] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Pyrexia AE (grade 3-4) | 0.95 [0.02, 47.95] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Rash AE (grade 3-4) | 0.95 [0.06, 15.23] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
| Thrombocytopenia AE (grade 3-4) | 0.03 [0.00, 0.42] | | < 1 | | 0% | 1 study (1/-) | 99.4 % | NA | not evaluable | | non important | - |
| Vomiting AE (grade 3-4) | 0.13 [0.02, 1.09] | | < 1 | | 0% | 1 study (1/-) | 96.9 % | NA | not evaluable | | non important | - |
| Weight decreased AE (grade 3-4) | 2.86 [0.30, 27.64] | | < 1 | | 0% | 1 study (1/-) | 18.3 % | NA | not evaluable | | non important | - |
